Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 12:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 267 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Comparator Challenge Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effects of Dopamine on Reward Processing

NCT01253421
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
amisulpride, placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Sep 10, 2026, 12:51 AM EDT
Terminated Phase 2 Interventional

A Safety and Efficacy Study of Xolair in Peanut Allergy

NCT00086606
View directory record Official record
Conditions
Allergy
Interventions
Xolair (omalizumab)
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
6 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 20, 2013 · Synced Sep 10, 2026, 12:51 AM EDT
Completed Not applicable Interventional Results available

Safe Administration of Flu Vaccine to Egg Allergic Children

NCT01264601
View directory record Official record
Conditions
Egg Allergy
Interventions
Trivalent Influenza Vaccine
Biological
Lead sponsor
University of Michigan
Other
Eligibility
6 Months to 24 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
San Diego, California • Ann Arbor, Michigan • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Sep 10, 2026, 12:51 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Efficacy, Safety and Immunogenicity of a Vaccine Designed to Protect Against Infection With Shigella Sonnei in Healthy Adults

NCT03527173
View directory record Official record
Conditions
Dysentery, Bacillary
Interventions
S.sonnei vaccine, Placebo, S. sonnei 53G challenge strain
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Sep 10, 2026, 12:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Eggshell Membrane Beauty From Within Trial

NCT06148337
View directory record Official record
Conditions
Skin Elasticity, Skin Hydration, Skin Barrier to Water Loss, Fingernail Health, Hair Health
Interventions
unhydrolyzed eggshell membrane, Placebo
Dietary Supplement
Lead sponsor
ESM Technologies, LLC
Industry
Eligibility
35 Years to 70 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 10, 2026, 12:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain

NCT04978454
View directory record Official record
Conditions
Influenza
Interventions
Influenza RG-A/Texas/71/2017 (H3N2) Challenge, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Sep 10, 2026, 12:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults

NCT04966871
View directory record Official record
Conditions
Malaria
Interventions
PfSPZ Vaccine, PfSPZ Challenge (7G8) for CHMI, Normal Saline
Biological · Other
Lead sponsor
Sanaria Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 17, 2022 · Synced Sep 10, 2026, 12:51 AM EDT
Recruiting Phase 2 Interventional

Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Levels and Atopic Dermatitis

NCT03835767
View directory record Official record
Conditions
Milk and/or Peanut Allergy
Interventions
Peanut powder and Oat flour, Peanut flour and Oat flour (placebo for peanut flour), Dry Milk Powder and Corn Starch (placebo for Milk powder), Baked milk and Rice milk (placebo for Baked milk)
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 21 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 10, 2026, 12:51 AM EDT
Completed Phase 2 Interventional Results available

Oral Immunotherapy for Childhood Egg Allergy

NCT00461097
View directory record Official record
Conditions
Hypersensitivity, Immediate Hypersensitivity, Food Hypersensitivity
Interventions
Egg oral immunotherapy, Control Group
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 18 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 10, 2026, 12:51 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of rEV131 in Allergic Rhinitis

NCT00247520
View directory record Official record
Conditions
Hay Fever
Interventions
topical nasal rEV131
Drug
Lead sponsor
Evolutec Group
Industry
Eligibility
18 Years to 80 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2005 · Synced Sep 10, 2026, 12:51 AM EDT
Not listed Phase 2 Interventional

A Study of the Safety, Efficacy and Tolerability of Nexvax-2 in Patients With Celiac Disease (CeD)

NCT03644069
View directory record Official record
Conditions
Celiac Disease, Celiac, Intestinal Disease, Malabsorption Syndromes, Gastrointestinal Disease, Digestive System Disease, Gluten Sensitivity, Autoimmune Diseases
Interventions
Nexvax2, Placebo
Biological
Lead sponsor
ImmusanT, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
28
States / cities
Walnut Creek, California • Stamford, Connecticut • Lighthouse PT, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 10, 2026, 12:51 AM EDT
Completed Phase 3 Interventional Results available

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

NCT03881696
View directory record Official record
Conditions
Peanut Allergy, Multi-food Allergy
Interventions
Omalizumab, Placebo for Omalizumab, Multi-Allergen Oral Immunotherapy, Placebo for Multi-Allergen Oral Immunotherapy, Double-Blind Placebo-Controlled Food Challenge Based Treatment
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 55 Years
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
10
States / cities
Little Rock, Arkansas • Stanford, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 10, 2026, 12:51 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study To Evaluate The Safety And Effects On The Body Of An Investigational Drug Using An Endotoxin-Induced Inflammatory Response Model

NCT01965600
View directory record Official record
Conditions
Healthy
Interventions
PF-06282999, Placebo, LPS
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 40 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Sep 10, 2026, 12:51 AM EDT
Completed Phase 3 Interventional Results available

PALISADE Follow-on Study (ARC004)

NCT02993107
View directory record Official record
Conditions
Peanut Allergy
Interventions
AR101
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
47
States / cities
Tucson, Arizona • Little Rock, Arkansas • Mission Viejo, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Sep 10, 2026, 12:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of SAGE-718 Using Ketamine Challenge in Healthy Subjects

NCT03844906
View directory record Official record
Conditions
Healthy Volunteer
Interventions
SAGE-718, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Long Beach, California • Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 10, 2026, 12:51 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of a Vaccine Against Enterotoxigenic Escherichia Coli (ETEC) to Prevent Moderate to Severe Diarrhea

NCT01060748
View directory record Official record
Conditions
Diarrhea
Interventions
ACE527, Placebo
Biological
Lead sponsor
TD Vaccines A/S
Industry
Eligibility
18 Years to 50 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 6, 2011 · Synced Sep 10, 2026, 12:51 AM EDT
Recruiting Phase 4 Interventional

Anti-Inflammatory Challenge in Schizophrenia

NCT05823532
View directory record Official record
Conditions
Schizophrenia
Interventions
Infliximab, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 10, 2026, 12:51 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

MIrabegron and Physiological Function in Cold Environments

NCT05990387
View directory record Official record
Conditions
Resting Energy Expenditure, Thermogenesis, Brown Adipose Tissue
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 10, 2026, 12:51 AM EDT
Completed Phase 2 Interventional Results available

OIT and Xolair® (Omalizumab) in Cow's Milk Allergy

NCT01157117
View directory record Official record
Conditions
Milk Allergy
Interventions
Placebo for omalizumab, Omalizumab, Milk powder
Biological · Drug
Lead sponsor
Hugh A Sampson, MD
Other
Eligibility
7 Years to 35 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Stanford, California • Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Sep 10, 2026, 12:51 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Spectroscopic Imaging at 4T: A Drug Challenge Study

NCT01577706
View directory record Official record
Conditions
AOD Effects and Consequences
Interventions
Alprazolam, Dextroamphetamine, Placebo
Drug · Other
Lead sponsor
Mclean Hospital
Other
Eligibility
21 Years to 45 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 10, 2026, 12:51 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Acute Effects of Ketone Supplement on Responses to Alcohol Challenge in Healthy Volunteers

NCT05551754
View directory record Official record
Conditions
Alcohol Drinking
Interventions
Ketone Supplement, Alcohol Beverage
Dietary Supplement · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 10, 2026, 12:51 AM EDT
Completed Phase 2 Interventional

A Study Of TL-925 For The Treatment of AC

NCT06293820
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
TL-925, Placebo
Drug
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 10, 2026, 12:51 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

BPL-1357 Against H1N1 Influenza Virus Challenge

NCT07215858
View directory record Official record
Conditions
Influenza, Human
Interventions
BPL-1357 IM, BPL-1357 IN, Placebo IM, Placebo IN
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Bethesda, Maryland • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 10, 2026, 12:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Challenges Without Prior Skin Testing

NCT03158831
View directory record Official record
Conditions
Drug Hypersensitivity, Penicillin Allergy, Antibiotic Allergy
Interventions
Placebo-Controlled Graded Drug Challenge
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
7 Years and older
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Sep 10, 2026, 12:51 AM EDT